Endocr Rev (1999) 20(1):68100
doi: 10.1016/j.cell.2013.02.035 68 De HaesWFrooninckxLVan AsscheRSmoldersADepuydtGBillenJet al
No evidence it causes cancer but could feed existing cancer
This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)
Further studies are needed to confirm the actual benefit of this molecule on metabolic liver diseases and define the best route of administration and the most appropriate dosage, allowing its use in clinical practice
1): (1) Rats in the normal control group got normal saline (0.9 % w/v, subcutaneously (s.c.)) once weekly for three weeks straight